In today's fast-paced technological advancements in medicine, the treatment of acute bacterial skin and skin structure ...
The patients all had some form of acute bacterial skin and skin structure infections (ABSSSI), including some with diabetic foot infections. R327G was also shown to be safe and well tolerated ...
Recce said the study would progress to a registrational phase 3 in acute bacterial skin and skin structure infections (ABSSSI) and diabetic foot infections (DFIs). The developer of a new class of ...
StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note issued to investors on Monday morning. The brokerage issued a hold rating on the ...
The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic ...
The Australian company’s open-label trial of Recce 327, a topical treatment designed to treat acute bacterial skin and skin structure infections (ABSSSI) and diabetic foot infections (DFIs ...
SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was ...
Stockhead on MSN4d
Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trialRecce has opted to carry out its phase III diabetic foot injury trial in Indonesia - which looks a safer bet than the US ...
SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback